Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

By sjmartinez • November 18, 2022

Wang X, Liu X, Hugo W, Si L, Shi H. Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments. Front Immunol. 2022 Oct 31;13:1065937. doi: 10.3389/fimmu.2022.1065937. PMID: 36389823; PMCID: PMC9661360.

Tags: Biomarker, combination therapy, Dermatology, immune checkpoint blockade (ICB), immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), melanoma, Publications

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and[...]

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee[...]

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients[...]